Capital Financial Group Inc. Co. ADV Takes Position in Gilead Sciences, Inc. $GILD

Capital Financial Group Inc. Co. ADV acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,219 shares of the biopharmaceutical company’s stock, valued at approximately $1,623,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Paulson Wealth Management Inc. lifted its holdings in Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. grew its position in Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 71 shares during the last quarter. Alpha Cubed Investments LLC grew its position in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 75 shares during the last quarter. Personal CFO Solutions LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 62,000 shares of company stock valued at $8,182,190 in the last ninety days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $124.30 on Tuesday. The firm has a fifty day moving average price of $132.86 and a two-hundred day moving average price of $134.32. The company has a market cap of $154.33 billion, a PE ratio of 16.93 and a beta of 0.31. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GILD. Barclays initiated coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Gilead Sciences in a research report on Tuesday, June 9th. Leerink Partners dropped their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Daiwa Securities Group dropped their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.